influenza
viru
respiratori
syncyti
viru
rsv
detect
short
turnaroundtim
tat
pivot
rapid
decis
regard
treatment
infect
control
howev
neg
rapid
test
result
may
come
poor
assay
sensit
influenzalik
ill
caus
communityacquir
respiratori
virus
carv
prospect
compar
perform
coba
liat
influenza
ab
rsv
assay
liat
routin
xtag
respiratori
pathogen
panel
luminex
eplexrpp
genmark
diagnost
use
consecut
nasopharyng
swab
patient
influenzalik
ill
winter
discord
result
reanalyz
specif
inhous
quantit
nucleic
acid
amplif
test
nat
liat
posit
influenza
virusa
b
rsv
sampl
neg
sampl
carv
detect
multiplexnat
sampl
concord
result
influenza
rsv
seen
discord
result
show
lowlevel
rsv
copiesml
sensit
specif
liat
influenzaa
b
rsv
respect
averag
tat
liat
minut
compar
hour
hour
respect
thu
liat
demonstr
excel
sensit
specif
influenza
rsv
togeth
simpl
sampl
process
short
tat
render
assay
suitabl
nearpati
test
influenza
viru
nucleic
acid
amplif
test
pointofcar
test
respiratori
syncyti
viru
turnaround
time
influenza
viru
respiratori
syncyti
viru
rsv
detect
short
turnaroundtim
tat
pivot
rapid
decis
regard
treatment
infect
control
current
diagnost
detect
influenza
viru
rsv
includ
direct
antigen
detect
dad
viru
isol
cell
cultur
vic
nucleic
acid
amplif
test
nat
dad
rapid
shown
limit
sensit
compar
vic
past
vic
gold
standard
sensit
specif
identif
communityacquir
respiratori
virus
carv
includ
influenza
virus
rsv
howev
vic
requir
skill
technician
dedic
cell
cultur
equip
tat
sever
day
limit
use
techniqu
special
laboratori
contrast
nat
advantag
shorter
tat
approxim
hour
detect
multipl
pathogen
parallel
test
semiquantit
format
multiplexnat
recent
nat
platform
becam
avail
detect
influenza
virus
pointofcar
test
poct
besid
short
tat
less
hour
cartridgebas
poct
simpl
oper
permit
use
nearpati
set
without
extens
laboratori
train
howev
neg
result
difficult
interpret
sinc
poct
j
med
virol
wileyonlinelibrarycomjournaljmv
may
limit
sensit
influenzalik
ill
question
may
due
carv
cover
poct
reason
comparison
multiplexnat
assay
consider
advantag
fact
number
centr
explor
deepsequenc
detect
carv
coba
liat
influenza
ab
rsv
realtim
assay
liat
interest
sinc
influenza
virusa
b
well
rsva
b
target
caus
signific
morbid
younger
children
older
adult
cold
season
therefor
guid
initi
decis
regard
antivir
therapi
well
infect
control
measur
first
phase
eight
extern
qualiti
assur
sampl
cover
influenza
virusa
b
rsv
test
liat
inhous
test
limit
detect
estim
use
twofold
serial
dilut
viru
transport
medium
vtm
patient
sampl
test
posit
either
influenza
rsv
inhous
quantit
nucleic
acid
amplif
qnat
assay
prospect
parallel
studi
consecut
nasopharyng
swab
submit
routin
test
novemb
januari
swab
compar
use
liat
two
food
drug
administr
fda
clear
multiplexnat
discord
result
liat
multiplexnat
resolv
inhous
realtim
qnat
briefli
nasopharyng
sampl
collect
use
copan
swab
adult
infant
submers
ml
vtm
liat
respiratori
specimen
transfer
singleus
dispos
assay
tube
use
steril
transfer
pipett
tube
cap
directli
insert
liat
analyz
inhous
qnat
influenza
virus
rsv
perform
previous
describ
briefli
revers
transcript
influenza
virusa
identifi
amplifi
specif
sequenc
matrix
protein
wherea
specif
hemagglutinin
sequenc
target
identifi
influenza
virusb
rsva
b
detect
duplex
qnat
amplifi
specif
sequenc
nonstructur
protein
c
qnat
reaction
incub
minut
minut
follow
cycl
second
minut
reaction
mix
total
volum
ad
extract
nucleic
acid
onestep
revers
transcript
amplif
sampl
test
duplic
addit
replic
spike
copi
respect
plasmid
detect
amplif
inhibit
viral
load
patient
sampl
determin
inhous
qnat
quantif
plasmid
contain
correspond
region
pathogen
genom
use
triplic
copi
gener
standard
curv
extern
qualiti
assur
program
test
differ
type
differ
dilut
influenza
rsv
use
valid
eight
extern
qualiti
assur
sampl
correctli
identifi
taken
togeth
liat
show
sensit
specif
influenza
virusa
influenza
virusb
rsv
respect
posit
predict
valu
neg
predict
valu
valu
interobserv
agreement
high
three
pathogen
tabl
multiplexnat
detect
addit
pathogen
figur
present
either
alon
case
coinfect
case
tabl
singl
infect
includ
adenoviru
human
bocaviru
coronavirus
human
metapneumoviru
parainfluenza
virus
rhinovirusenteroviru
year
thu
strong
trend
seen
male
gender
reach
statist
signific
p
observ
sole
base
demograph
would
requir
dedic
clinicaldiagnost
studi
howev
report
other
children
male
gender
may
suscept
sever
respiratori
diseas
manifest
coinfect
rsv
influenza
virusa
found
togeth
pathogen
influenza
virusb
found
coinfect
tabl
tabl
influenza
virusb
case
sampl
neg
test
twice
neg
inhous
qnat
repeat
test
liat
possibl
due
lack
sampl
materi
rsv
case
liat
score
three
sampl
posit
test
neg
multiplexnat
two
sampl
one
sampl
discord
result
resolv
inhous
qnat
viral
load
copiesml
vtm
respect
suggest
limit
sensit
multiplexnat
possibl
due
multiplex
target
sequenc
issu
detect
copiesml
vtm
qnat
one
liat
rsvposit
sampl
line
result
copiesml
vtm
rsv
detect
sensit
influenza
virusa
copiesml
vtm
influenza
virusb
copi
ml
vtm
similar
rang
therebi
permit
detect
acut
ill
patient
typic
much
higher
viral
load
previou
studi
liat
compar
commerci
nat
result
studi
suggest
liat
superior
sensit
compar
poct
howev
sampl
age
rang
mostli
obtain
adult
patient
complement
studi
major
symptomat
children
tabl
follow
limit
note
first
batch
test
patient
sampl
possibl
peak
season
influenza
rsv
sequenti
test
may
result
loss
tat
advantag
sampl
per
hour
per
hour
per
hour
howev
partli
compens
direct
parallel
test
one
liat
instrument
second
liat
lack
identif
influenza
virusa
subtyp
detect
influenza
virusa
subtyp
may
influenc
isol
procedur
hospit
set
addit
immunocompromis
patient
may
risk
dual
infect
rare
usual
one
pathogen
domin
case
subsequ
multiplexnat
qnat
provid
semiquantit
result
help
identifi
main
driver
infect
liat
easi
handl
test
system
may
attract
use
personnel
train
profession
laboratori
analyst
howev
practic
qualif
program
correspond
document
requalif
everi
year
need
perform
accord
laboratori
regul
fail
intern
extern
qualiti
assur
program
conclus
liat
reduc
tat
compar
convent
multiplexnat
qnat
studi
sensit
liat
seem
equival
slightli
increas
current
multiplexnat
compar
specif
qnat
specif
similar
multiplexnat
thu
liat
seem
use
rapid
test
manag
decis
regard
infect
control
therapi
could
follow
qnat
document
viral
replic
clearanc
need
andor
multiplexnat
detect
respiratori
pathogen
